The prostate cancer landscape is complex, covering multiple clinical stages including localized disease, biochemical recurrence (rising PSA), metastatic disease, and ultimately castration resistance. With numerous approvals over the last decade, the landscape continues to evolve. Androgen receptor-targeted therapies are moving into earlier clinical stages and precision medicine is emerging. Efforts also continue to turn this “cold” tumor “hot” and identify a role for immunotherapy.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in prostate cancer to help guide strategic and tactical commercial development decisions for market participants.